Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.95 USD | +3.26% | -3.56% | -9.52% |
Apr. 01 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 26 | Transcript : Quince Therapeutics, Inc. - Special Call |
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 45.01M |
---|---|---|---|---|---|
Net income 2022 | -51M | Net income 2023 | -31M | EV / Sales 2022 | - |
Net cash position 2022 | 89.73M | Net cash position 2023 | 61.24M | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.41
x | P/E ratio 2023 |
-1.25
x | Employees | 32 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 86.93% |
Latest transcript on Quince Therapeutics, Inc.
1 day | +3.26% | ||
1 week | -3.56% | ||
Current month | -11.21% | ||
1 month | -4.04% | ||
3 months | -26.92% | ||
6 months | +5.37% | ||
Current year | -9.52% |
Managers | Title | Age | Since |
---|---|---|---|
Dirk Thye
CEO | Chief Executive Officer | 54 | 22-05-18 |
Brendan Hannah
DFI | Director of Finance/CFO | 39 | 22-04-30 |
Charles Ryan
PSD | President | 60 | 23-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Una Ryan
BRD | Director/Board Member | 82 | 18-02-28 |
Luca Benatti
BRD | Director/Board Member | 63 | 23-10-22 |
Dirk Thye
CEO | Chief Executive Officer | 54 | 22-05-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 0.95 | +3.26% | 134,198 |
24-05-09 | 0.92 | +1.10% | 41,972 |
24-05-08 | 0.91 | -1.09% | 169,176 |
24-05-07 | 0.92 | -4.17% | 194,007 |
24-05-06 | 0.96 | -2.55% | 57,847 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-9.52% | 41.05M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- QNCX Stock